Peoples Financial Services CORP. lifted its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 12.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 44,843 shares of the biopharmaceutical company’s stock after acquiring an additional 5,075 shares during the period. Bristol-Myers Squibb makes up 1.4% of Peoples Financial Services CORP.’s portfolio, making the stock its 19th largest holding. Peoples Financial Services CORP.’s holdings in Bristol-Myers Squibb were worth $2,784,000 as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in the company. Sciencast Management LP bought a new position in Bristol-Myers Squibb in the first quarter worth $602,000. WealthPLAN Partners LLC lifted its position in Bristol-Myers Squibb by 240.9% in the first quarter. WealthPLAN Partners LLC now owns 20,040 shares of the biopharmaceutical company’s stock worth $1,268,000 after purchasing an additional 14,161 shares during the period. Nexthera Capital LP lifted its holdings in shares of Bristol-Myers Squibb by 15.8% during the first quarter. Nexthera Capital LP now owns 342,399 shares of the biopharmaceutical company’s stock valued at $21,657,000 after acquiring an additional 46,799 shares during the period. Garde Capital Inc. bought a new position in shares of Bristol-Myers Squibb during the first quarter valued at $305,000. Finally, Private Capital Group LLC lifted its holdings in shares of Bristol-Myers Squibb by 41.0% during the first quarter. Private Capital Group LLC now owns 11,052 shares of the biopharmaceutical company’s stock valued at $699,000 after acquiring an additional 3,214 shares during the period. Institutional investors and hedge funds own 72.28% of the company’s stock.
Bristol-Myers Squibb stock opened at $57.51 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.40 and a quick ratio of 1.28. Bristol-Myers Squibb Co has a 12-month low of $49.96 and a 12-month high of $70.05. The stock has a market capitalization of $101.47 billion, a P/E ratio of 19.11, a price-to-earnings-growth ratio of 1.70 and a beta of 0.98.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported $1.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.87 by $0.14. Bristol-Myers Squibb had a return on equity of 42.58% and a net margin of 1.74%. The business had revenue of $5.70 billion during the quarter, compared to analysts’ expectations of $5.48 billion. During the same period in the previous year, the business posted $0.74 earnings per share. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. As a group, sell-side analysts predict that Bristol-Myers Squibb Co will post 3.62 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, November 1st. Investors of record on Friday, October 5th will be issued a $0.40 dividend. The ex-dividend date is Thursday, October 4th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.78%. Bristol-Myers Squibb’s dividend payout ratio is 53.16%.
A number of research analysts have issued reports on the company. SunTrust Banks reissued a “buy” rating and set a $67.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, July 31st. JPMorgan Chase & Co. lifted their price objective on Bristol-Myers Squibb from $70.00 to $74.00 and gave the company an “overweight” rating in a report on Monday, October 8th. ValuEngine raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, July 14th. BMO Capital Markets lifted their price objective on Bristol-Myers Squibb from $47.00 to $51.00 and gave the company a “market perform” rating in a report on Monday, July 23rd. Finally, Credit Suisse Group lifted their price objective on Bristol-Myers Squibb from $58.00 to $61.00 and gave the company a “neutral” rating in a report on Friday, July 27th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $62.95.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Further Reading: The Role of a Fiduciary and Individual Investors
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.